As precision oncology continues to advance, HER2 (human epidermal growth factor receptor 2) has become one of the most mature and clinically valuable therapeutic targets across multiple solid tumors. With an improved understanding of tumor heterogeneity and mechanisms of drug resistance, the limitations of single-target, single-mechanism treatment strategies have become increasingly evident....